JUVABIS
Juvabis is a startup company that designs next-generation aminoglycoside antibiotics that withstand mechanisms of bacterial drug-resistance. The company has been founded around a proprietary technology developed by researchers at the University of Zurich, and a pipeline of early drug candidates discovered in collaboration with researchers at the ETH Zurich and Wayne State University in Detroit.
JUVABIS
Social Links:
Industry:
Biotechnology Life Science Pharmaceutical
Address:
Frutigen, Bern, Switzerland
Country:
Switzerland
Website Url:
http://www.juvabis.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
IPv6 Cloudflare Hosting Cloudflare DNS
Current Employees Featured
Founder
Newest Events participated
Official Site Inspections
http://www.juvabis.com
- Host name: 104.21.96.19
- IP address: 104.21.96.19
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Juvabis"
Juvabis
Juvabis’ “best-in-class” anti-infective drug EBL1003 is currently in clinical trials phase 1. EBL-1003 is designed as an antibiotic-combination therapy for the treatment of critically-ill patients in …See details»
Juvabis - Crunchbase Company Profile & Funding
Juvabis is a startup company that designs next-generation aminoglycoside antibiotics that withstand mechanisms of bacterial drug-resistance. The company has been founded around a …See details»
Juvabis Company Profile 2024: Valuation, Funding & Investors
Juvabis General Information Description. Developer of a biopharmaceutical technology designed to create next-generation therapeutics against bacterial infections. The company's platform …See details»
Juvabis - Products, Competitors, Financials, Employees, …
Juvabis is a clinical-stage biopharmaceutical company focused on developing therapies against bacterial infections. The company's main offerings include best-in-class therapeutic drugs …See details»
Juvabis - VentureRadar
Juvabis designs next-generation aminoglycoside antibiotics that withstand mechanisms of bacterial drug-resistance and at the same time display superior tolerability due to increased …See details»
Juvabis - Contacts, Employees, Board Members, Advisors & Alumni
Juvabis is a startup company that designs next-generation aminoglycoside antibiotics that withstand mechanisms of bacterial drug-resistance. ... Chrome Extension. Solutions. Products. …See details»
Juvabis AG - Zürich, Switzerland - bionity.com
The Swiss start-up company Juvabis designs next-generation aminoglycoside antibiotics that withstand mechanisms of bacterial drug-resistance and at the same time display superior …See details»
Juvabis AG Company Profile | Zürich, ZÜRICH, Switzerland
Find company research, competitor information, contact details & financial data for Juvabis AG of Zürich, ZÜRICH. Get the latest business insights from Dun & Bradstreet.See details»
Juvabis - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Juvabis is a startup company that designs next-generation aminoglycoside antibiotics that withstand mechanisms of bacterial drug-resistance. Search Crunchbase Start Free TrialSee details»
Juvabis - Company Profile - Tracxn
Juvabis - Developer of therapeutic solutions for the treatment of bacterial infectious diseases. from 1 investor. Founded by Sven N Hobbie, Andrea Vasella and 2 others in the year 2015. …See details»
Juvabis AG - startup.ch
Juvabis holds an exclusive worldwide license for a strong IP portfolio invented at the ETH and University of Zurich by its co-founders. Juvabis has the most advanced antibiotic asset within …See details»
Juvabis - Crunchbase
Juvabis is a startup company that designs next-generation aminoglycoside antibiotics that withstand mechanisms of bacterial drug-resistance. Search Crunchbase. Start Free Trial . …See details»
Juvabis AG - startupticker.ch
Mar 27, 2019 Register and get more services Create your personal archive Get the Newsletter Set award alarms. Get involvedSee details»
Juvabis AG - Venturelab
Jun 30, 2015 Juvabis holds an exclusive worldwide license for a strong IP portfolio invented at the ETH and University of Zurich by its co-founders. Juvabis has the most advanced antibiotic …See details»
Juvabis: Positive Phase I results for infection treatment caused by ...
Juvabis AG, a clinical-stage biopharmaceutical company focused on discovering and developing treatments in areas of high unmet medical need involving multidrug-resistant bacterial …See details»
Nextsource | Company Profile | Juvabis
Monitor if Juvabis is shifting their marketing strategy based on recent ad campaigns or rebranding efforts. Find out if Juvabis has recently secured any major clients or partnerships. Track key …See details»
Meet Venture Leader Sven N. Hobbie's Next-Generation …
May 21, 2019 Ten Venture Leaders will represent Switzerland in Boston in June. Meet Sven N. Hobbie, co-founder and CEO of Juvabis. Learn more on gram-negative systemic infections, …See details»
New substance offers hope for a cure against multi-resistant bacteria
The Swiss biotech company Juvabis is developing a new substance, EBL-1003, as part of the ENABLE project. The substance could be used to treat patients with illnesses caused by multi …See details»
☑️Juvabis AG — Consulting Organization from
Juvabis AG — Consulting Organization from Switzerland, has experience with The Seventh Framework Programme, it`s involved in Health, Science & Innovation sectorsSee details»